en Tildipirosin

Tildipirosin
Clinical data
Trade names	Zuprevo
License data	US DailyMed: Tildipirosin;
Routes of; administration	Intramuscular, subcutaneous
ATCvet code	QJ01FA96 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only; EU: Rx-only;
Identifiers
	IUPAC name (4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4S,5S,6R)-4-(Dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-5,9,13-trimethyl-7-(2-piperidin-1-ylethyl)-15-(piperidin-1-ylmethyl)-1-oxacyclohexadeca-11,13-diene-2,10-dione; (4R,5S,6S,7R,9R,11E,13E,15R,16R)-16-Ethyl-4-hydroxy-5,9,13-trimethyl-2,10-dioxo-7-[2-(1-piperidinyl)ethyl]-15-(1-piperidinylmethyl)oxacyclohexadeca-11,13-dien-6-yl 3,6-dideoxy-3-(dimethylamino)-β-D-glucopyranoside; ; ;
CAS Number	328898-40-4;
PubChem CID	24860548;
DrugBank	DB11470;
ChemSpider	30790722;
UNII	S795AT66JB;
ChEMBL	ChEMBL3039509;
CompTox Dashboard (EPA)	DTXSID70954546 ;
ECHA InfoCard	100.168.011
Chemical and physical data
Formula	C41H71N3O8
Molar mass	734.032 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CCN3CCCCC3)C)\C)CN4CCCCC4;
	InChI InChI=1S/C41H71N3O8/c1-8-35-32(26-44-20-13-10-14-21-44)23-27(2)15-16-33(45)28(3)24-31(17-22-43-18-11-9-12-19-43)40(29(4)34(46)25-36(47)51-35)52-41-39(49)37(42(6)7)38(48)30(5)50-41/h15-16,23,28-32,34-35,37-41,46,48-49H,8-14,17-22,24-26H2,1-7H3/b16-15+,27-23+/t28-,29+,30-,31+,32-,34-,35-,37+,38-,39-,40-,41+/m1/s1; Key:HNDXPZPJZGTJLJ-UEJFNEDBSA-N;

Tildipirosin, sold under the brand name Zuprevo, is a macrolide antibiotic used in pigs and cattle.^[1]^[3]

Medical uses

In the United States, tildipirosin is indicated for the treatment or control of bovine respiratory disease associated with Mannheimia haemolytica, Pasteurella multocida, and Histophilus somni in beef and non-lactating dairy cattle.^[1]

In the European Union, tildipirosin is indicated for the treatment and metaphylaxis of swine respiratory disease associated with Actinobacillus pleuropneumoniae, P. multocida, Bordetella bronchiseptica, and Glaesserella parasuis sensitive to tildipirosin;^[3] and for the treatment and prevention of bovine respiratory disease associated with M. haemolytica, P. multocida]], and H. somni sensitive to tildipirosin.^[3]

References

^ ^a ^b ^c "Zuprevo- tildipirosin injection, solution". DailyMed. U.S. National Library of Medicine. 11 January 2013. Retrieved 21 August 2023.
^ Budde JA, McCluskey DM (2023). Plumb's Veterinary Drug Handbook (Tenth ed.). Wiley. p. 1235. ISBN 978-1-394-17220-7.
^ ^a ^b ^c ^d "Zuprevo EPAR". European Medicines Agency. 3 February 2022. Retrieved 21 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[Zuprevo_FDA_label-1] "Zuprevo- tildipirosin injection, solution". DailyMed. U.S. National Library of Medicine. 11 January 2013. Retrieved 21 August 2023.

[2] Budde JA, McCluskey DM (2023). Plumb's Veterinary Drug Handbook (Tenth ed.). Wiley. p. 1235. ISBN 978-1-394-17220-7.

[Zuprevo_EPAR-3] "Zuprevo EPAR". European Medicines Agency. 3 February 2022. Retrieved 21 August 2023. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[1]

[2]

[3]